Skip to main content
Figure 3 | BMC Biotechnology

Figure 3

From: Engineering of the LukS-PV and LukF-PV subunits of Staphylococcus aureusPanton-Valentine leukocidin for Diagnostic and Therapeutic Applications

Figure 3

Expression and Ni++-affinity purification of S and F protein subunits. A. Over-expression of fusion LukS-PV and LukF-PV (10% SDS-PAGE) Lane 1, Protein Mw standard; Lanes 2 & 3, Total soluble lysate of E. coli BL21(DE3)pLysS-pET-21d(+)-lukF-PV after induction with IPTG; Lanes 4 & 5, Total soluble lysate of E. coli BL21(DE3)pLysS-pET-21d(+)-lukS-PV after induction with IPTG; Lane 6, Uninduced E. coli BL21(DE3)-pET-21d(+)-lukS-PV; Lane 7, Un induced E. coli BL21(DE3)-pET-21d(+)-lukF-PV. 3B and C. Purity of His-Tagged LukS-PV and LukF-PV following Nickel Affinity chromatography. B. Lane 1, Total soluble lysate of E. coli BL21(DE3)pLysS-pET-21d(+)-lukF-PV after induction with IPTG; Lane 2, Purified 6His-LukF-PV; Lane 3, Protein Mw standard. C. Purity of His-Tagged LukS-PV following Nickel Affinity chromatography. Lane 1, Protein Mw standard; Lane 2, Total soluble lysate of E. coli BL21(DE3)pLysS-pET-21d(+)-lukS-PV after induction with IPTG; Lane 3, water; Lanes 4, 5 & 6, Eluate without His-Tagged LukS-PV; Lanes 7, 8, 9 & 10, Eluate containing His-Tagged LukS-PV.

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us